My Companies
Notification
Account
Log Out
Back

AstraZeneca Pharma India Secures CDSCO Nod For Enhertu Additional Breast Cancer Indication

28 July 2026
Astrazeneca Pharma India Ltd.

Received CDSCO approval for Trastuzumab Deruxtecan (Enhertu®) for neoadjuvant treatment of HER2-positive Stage II/III breast cancer, following THP therapy. Expands Enhertu's market, reinforcing oncology portfolio.

Recent Events

8 August 2026

AstraZeneca Pharma India Receives CDSCO Permission For Enhertu Breast Cancer Indication
16 July 2026

AstraZeneca Pharma India Secures CDSCO Approval for Benralizumab HES Indication

Real time WhatsApp alerts using AI.

Get features of

  • Instant Notifications
  • Competitive Advantage
  • Critical Alerts
Signup or Sign in

Company Information